PubRank
Search
About
Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma
Clinical Trial ID NCT01024231
PubWeight™ 61.46
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT01024231
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Nivolumab plus ipilimumab in advanced melanoma.
N Engl J Med
2013
17.53
2
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps.
Nat Rev Cancer
2011
6.44
3
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
Clin Cancer Res
2013
3.48
4
Deciphering and reversing tumor immune suppression.
Immunity
2013
2.24
5
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma.
Ann N Y Acad Sci
2013
2.03
6
PD-1 as a potential target in cancer therapy.
Cancer Med
2013
1.98
7
At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.
J Leukoc Biol
2013
1.90
8
Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.
J Clin Invest
2015
1.67
9
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Trends Mol Med
2014
1.59
10
The role of B7 family molecules in hematologic malignancy.
Blood
2012
1.47
11
Molecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapy.
Clin Cancer Res
2013
1.39
12
Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.
Endocr Relat Cancer
2014
1.32
13
Combination immune therapies to enhance anti-tumor responses by NK cells.
Front Immunol
2013
1.29
14
Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.
Oncoimmunology
2014
1.22
15
Pathways and therapeutic targets in melanoma.
Oncotarget
2014
1.17
16
Prostate cancer immunotherapy.
Clin Cancer Res
2011
1.11
17
Immunomodulatory therapy for melanoma: ipilimumab and beyond.
Clin Dermatol
2013
1.04
18
Targeting immune checkpoints: releasing the restraints on anti-tumor immunity for patients with melanoma.
Cancer J
2012
0.97
19
Rationale for targeting the immune system through checkpoint molecule blockade in the treatment of non-small-cell lung cancer.
Ann Oncol
2013
0.96
20
Checkpoint modulation in melanoma: an update on ipilimumab and future directions.
Curr Oncol Rep
2013
0.94
21
The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
Cancer
2016
0.92
22
New combinations and immunotherapies for melanoma: latest evidence and clinical utility.
Ther Adv Med Oncol
2013
0.92
23
Immune checkpoint blockade in cancer treatment: a double-edged sword cross-targeting the host as an "innocent bystander".
Toxins (Basel)
2014
0.92
24
Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigm.
Mol Cancer Ther
2012
0.91
25
Targeting the PD-1 pathway: a promising future for the treatment of melanoma.
Arch Dermatol Res
2014
0.87
26
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".
J Transl Med
2012
0.87
27
Combined targeted therapy and immunotherapy in the treatment of advanced melanoma.
Oncoimmunology
2012
0.87
28
Metastatic melanoma - a review of current and future drugs.
Drugs Context
2012
0.83
29
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Immunotherapy
2014
0.81
30
PD-1 and PD-L1 antibodies for melanoma.
Hum Vaccin Immunother
2014
0.80
31
Biomarkers as key contributors in treating malignant melanoma metastases.
Dermatol Res Pract
2011
0.79
32
Combinatorial Immunotherapy: PD-1 may not be LAG-ing behind any more.
Oncoimmunology
2012
0.78
33
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.
J Transl Med
2016
0.77
34
Immunotherapy for prostate cancer enters its golden age.
Clin Med Insights Oncol
2012
0.77
35
The role of checkpoints in the treatment of GBM.
J Neurooncol
2015
0.75
36
Adding fuel to the fire: immunogenic intensification.
Hum Vaccin Immunother
2014
0.75
37
Cyclosporine for Dry Eye Associated With Nivolumab: A Case Progressing to Corneal Perforation.
Cornea
2016
0.75
Next 100